{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:56:47Z","timestamp":1770897407402,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]},{"name":"BMS"},{"name":"ViiV"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Gilead"},{"name":"Astra Zeneca"},{"DOI":"10.13039\/100015756","name":"Janssen Cilag","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ViiV"},{"name":"Astellas"},{"name":"Abbott"},{"name":"Gilead"},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol-Myers Squibb"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.cmi.2017.07.021","type":"journal-article","created":{"date-parts":[[2017,7,29]],"date-time":"2017-07-29T20:01:53Z","timestamp":1501358513000},"page":"422-427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015"],"prefix":"10.1016","volume":"24","author":[{"given":"B.","family":"Rossetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tavelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Antinori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pellizzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cozzi-Lepri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bonora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.d'Arminio","family":"Monforte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Puoti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2017.07.021_bib1","series-title":"Global health sector strategy on viral hepatitis","year":"2016"},{"key":"10.1016\/j.cmi.2017.07.021_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis","author":"Platt","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2017.07.021_bib3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/apc.2015.0004","article-title":"Majority of HIV\/HCV patients need to switch antiretroviral therapy to accommodate direct acting antivirals","volume":"29","author":"Cope","year":"2015","journal-title":"AIDS Patient Care and STDS"},{"key":"10.1016\/j.cmi.2017.07.021_bib4","series-title":"Global health observatory: HIV\/AIDS","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.cmi.2017.07.021_bib5","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/QAD.0b013e32833a0918","article-title":"Factors associated with specific causes of death amongst HIV-positive individuals in the D: A:D Study","volume":"24","author":"Smith","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.cmi.2017.07.021_bib6","doi-asserted-by":"crossref","first-page":"ofv168","DOI":"10.1093\/ofid\/ofv168","article-title":"The impact of direct-acting antivirals in the hepatitis C sustained viral response in human immunodeficiency virus-infected patients with ongoing barriers to care","volume":"2","author":"Cachay","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2017.07.021_bib7","doi-asserted-by":"crossref","first-page":"e102883","DOI":"10.1371\/journal.pone.0102883","article-title":"The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care","volume":"9","author":"Cachay","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2017.07.021_bib8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/hep.26741","article-title":"Fibrosis progression in human immunodeficiency virus\/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs","volume":"59","author":"Konerman","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2017.07.021_bib9","unstructured":"AASLD\/IDSA\/IAS\u2014USA: Recommendations for testing, managing, and treating hepatitis C. Available at: http:\/\/www.hcvguidelines.org (accessed 3 July 2017)."},{"key":"10.1016\/j.cmi.2017.07.021_bib10","first-page":"423","article-title":"Recommendations for the use of hepatitis C virus protease inhibitors for the treatment of chronic hepatitis C in HIV-infected persons. A position paper of the Italian Association for the Study of Infectious and Tropical Disease","volume":"37","author":"Armignacco","year":"2014","journal-title":"New Microbiol"},{"key":"10.1016\/j.cmi.2017.07.021_bib11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/hiv.12429","article-title":"Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV\/HIV-coinfected patients: real-life safety and efficacy","volume":"18","author":"Milazzo","year":"2017","journal-title":"HIV Med"},{"key":"10.1016\/j.cmi.2017.07.021_bib12","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10865-016-9778-y","article-title":"Assessment of factors associated with the quality of life of patients living with HIV\/HCV co-infection","volume":"39","author":"Pereira","year":"2016","journal-title":"J\u00a0Behav Med"},{"key":"10.1016\/j.cmi.2017.07.021_bib13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1310\/hct1303-142","article-title":"Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial","volume":"13","author":"Rodriguez-Torres","year":"2012","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.cmi.2017.07.021_bib14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2011.05.032","article-title":"Gaps in the achievement of effectiveness of HCV treatment in national VA practice","volume":"56","author":"Kramer","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2017.07.021_bib15","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrgastro.2011.21","article-title":"Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.","volume":"8","author":"Sulkowski","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2017.07.021_bib16","doi-asserted-by":"crossref","first-page":"234","DOI":"10.14218\/JCTH.2016.00026","article-title":"HIV\/HCV antiviral drug interactions in the era of direct-acting antivirals","volume":"4","author":"Rice","year":"2016","journal-title":"J\u00a0Clin Transl Hepatol"},{"key":"10.1016\/j.cmi.2017.07.021_bib17","doi-asserted-by":"crossref","first-page":"e0177402","DOI":"10.1371\/journal.pone.0177402","article-title":"Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort","volume":"12","author":"D'Arminio Monforte","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2017.07.021_bib18","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2017.07.021_bib19","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jama.2012.7844","article-title":"Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV\/HCV","volume":"308","author":"Limketkai","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2017.07.021_bib20","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1473-3099(13)70059-8","article-title":"Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial","volume":"13","author":"Deterding","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2017.07.021_bib21","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nature08463","article-title":"Genetic variation in IL28B and spontaneous clearance of hepatitis C virus","volume":"461","author":"Thomas","year":"2009","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1016\/j.cmi.2017.07.021_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/liv.13021","article-title":"HCV-HIV co-infected patients: no longer a \u201cspecial\u201d population?","volume":"36","author":"Sulkowski","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.cmi.2017.07.021_bib23","first-page":"e12","article-title":"Cohort Profile: Standardized management of Antiretroviral Therapy Cohort (MASTER Cohort)","volume":"46","author":"Torti","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.cmi.2017.07.021_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/CMR.13.2.223","article-title":"Clinical significance of hepatitis C virus genotype","volume":"13","author":"Zein","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2017.07.021_bib25","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.3390\/v7092857","article-title":"Genetic diversity and selective pressure in hepatitis C virus genotypes 1\u20136: significance for direct-acting antiviral treatment and drug resistance","volume":"7","author":"Cuypers","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2017.07.021_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13027-016-0099-0","article-title":"Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe","volume":"11","author":"Petruzziello","year":"2016","journal-title":"Infect Agent Cancer"},{"key":"10.1016\/j.cmi.2017.07.021_bib27","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1002\/jmv.24573","article-title":"Literature review of the distribution of hepatitis C virus genotypes across Europe","volume":"88","author":"Alberti","year":"2016","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.cmi.2017.07.021_bib28","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/liv.12848","article-title":"Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?","volume":"35","author":"Boesecke","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.cmi.2017.07.021_bib29","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/QAD.0000000000000674","article-title":"Liver-related death among HIV\/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals","volume":"29","author":"Grint","year":"2015","journal-title":"AIDS"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X17304056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X17304056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:21:34Z","timestamp":1761117694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X17304056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1198743X17304056"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2017.07.021","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2017.07.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}